Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040541 · ClinicalTrials.gov registry record · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 604
- Enrollment target
- 17
- Study locations
NCT06040541: Recruiting Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.
NCT06040541 is a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 604 participants, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (210% higher). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06040541, a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 604 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Primary Outcome
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs
Conditions Studied
Interventions
- DRUG RMC-6236
- DRUG RMC-9805
Study Locations (17)
Texas
- Sarah Cannon Research Institute at Mary Crowley - Dallas
- University of Texas, MD Anderson Cancer Center - Houston
- START - San Antonio
Florida
- Florida Cancer Specialists - Sarasota
- Lee Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke Cancer Center - Durham
- Carolina BioOncology Institute - Huntersville
California
- University of California, Davis Comprehensive Cancer Center - Sacramento
Connecticut
- Smilow Cancer Hospital (Yale University) - New Haven
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
What NCT06040541 shows while recruiting
NCT06040541 is an interventional study that assigns participants to a tested intervention. The registered 604 participants enrollment target is mid-sized for trials with a published cap, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (210% higher).
The record links to 4 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which RMC-6236 is the first listed.
NCT06040541 lists 17 locations in 11 states (Texas, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06040541 about?
NCT06040541 is a clinical study titled "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors". This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
What is the current status of trial NCT06040541?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 604 participants. The study started on 2023-09-07. Estimated completion is 2027-04-30.
What conditions does trial NCT06040541 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT06040541?
The interventions under investigation include: RMC-6236 (DRUG), RMC-9805 (DRUG).
Who is sponsoring clinical trial NCT06040541?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06040541 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06040541's enrollment target sits among peer trials
604 7th of 144 higher than 138 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI